Clinical trials: Ranibizumab
Angioid Streaks
Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
- Trial name
- NCT01015495
- Testing
- ranibizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Wet AMD
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.
- Trial name
- NCT00804934
- Testing
- Lucentis
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Cystoid Macular Edema
Lucentis for Treatment of Macular Edema
Cystoid macular edema (CME) is the most common cause of suboptimal post-operative visual acuity in uncomplicated cataract extractions.
- Trial name
- FVF4153s (NCT00464581)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Patients With Primary Nasal Pterygium
Effects of Ranibizumab in Primary Pterygium Surgery
Pterygium is a common ocular surface disease in Malaysia. Without treatment, it can lead to severe visual impairment. Recurrence is the commonest complication and novel treatment approaches are crucial to prevent vision loss.
- Trial name
- NCT04878835
- Testing
- intralesional ranibizumab
- Where
- Malaysia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia
Macular Degeneration, Choroidal Neovascularization
Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging
Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.
- Trial name
- NCT03105609
- Testing
- Hyperspectral imaging
- Where
- Australia
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Age-related Macular Degeneration, Coronary Artery Disease
Ranibizumab and the Risk of Arterial Thromboembolic Events
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events.
- Conditions
- Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders
- Trial name
- RATE (NCT01319188)
- Testing
- 0.5 mg of ranibizumab, 0.5 mg of ranibizumab + photodynamic therapy
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Ural State Medical University
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Ophthalmopathy
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO
- Trial name
- NCT04460001
- Testing
- Ranibizumab, triamcinolone acetate
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Age Related Macular Degeneration
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
This is a single-masked study to compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal…
- Trial name
- LAST (NCT01115556)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Diabetic Macular Oedema
To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus
To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.
- Trial name
- CONTROL (NCT03495765)
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Marsden Eye Specialists
Choroidal Melanoma
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the…
- Trial name
- NCT00680225
- Testing
- Ranibizumab injection and TTT - ICG based
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- New England Retina Associates
Retinal Hemorrhage, Macular Degeneration
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor.
- Trial name
- NCT00538538
- Testing
- vitrectomy with subretinal lucentis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Corewell Health East